Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 7/20 | 0.45 |
| ▸ | RPS6KA4 | O75676 | 3/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 10/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5738350 | 0.77 | RPS6KA5 (0.46) | RPS6KA5RPS6KA4EGFR | |
| SCHEMBL7975279 | 0.76 | RPS6KA5 (0.40) | RPS6KA5RPS6KA4EGFR | |
| SCHEMBL3262202 | 0.75 | RPS6KA5 (0.53) | RPS6KA5RPS6KA4EGFR | |
| SCHEMBL8097276 | 0.75 | RPS6KA5 (0.45) | RPS6KA5RPS6KA4EGFR | |
| SCHEMBL12775613 | 0.75 | RPS6KA5 (0.42) | RPS6KA5RPS6KA4EGFR | |
| SCHEMBL19250468 | 0.75 | RPS6KA5 (0.42) | RPS6KA5RPS6KA4PIK3CBEGFR | |
| SCHEMBL12844573 | 0.75 | RPS6KA5 (0.42) | RPS6KA5RPS6KA4EGFR | |
| SCHEMBL30816161 | 0.73 | BRD9 (0.54) | EGFRBRD9 | |
| SCHEMBL24670232 | 0.72 | PIK3C3 (0.43) | RPS6KA5RPS6KA4EGFR | |
| SCHEMBL28835788 | 0.71 | RPS6KA5 (0.42) | RPS6KA5RPS6KA4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009013545-A2 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | WO | claimed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| WO-2021038095-A1 | PEPTIDES AND METHODS FOR THE CARBON-CARBON BOND FORMATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-03-04 | — | — | WO | disclosed |
| EP-3786290-A1 | PEPTIDES AND METHODS FOR THE CARBON-CARBON BOND FORMATION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-03-03 | — | — | EP | disclosed |
| WO-2020120420-A1 | METHOD FOR PREPARATION OF PRIMARY AMINE COMPOUNDS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-06-18 | — | — | WO | disclosed |
| US-20190292189-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC | 2019-09-26 | — | — | US | disclosed |
| WO-2017201187-A1 | LIM KINASE INHIBITORS | VIRONGY, LLC (US) | 2017-11-23 | — | — | WO | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2003-02-20 | — | — | US | disclosed |
| EP-1246623-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2002057267-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-07-18 | — | — | US | disclosed |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2002-05-16 | — | — | US | disclosed |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
| EP-1082120-A1 | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE | OSI Pharmaceuticals, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999062518-A1 | PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE | OSI PHARMACEUTICALS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | RPS6KA5 117/4885RPS6KA4 132/4885PIK3CB 30/4885 |
| US-20020058667-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | RPS6KA5 2115/4885RPS6KA4 2283/4885PIK3CB 2377/4885 |
| US-20030045536-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | RPS6KA5 2115/4885RPS6KA4 2283/4885PIK3CB 2377/4885 |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | RPS6KA5 400/4885RPS6KA4 567/4885PIK3CB 361/4885 |
| US-20030036545-A1 | Compounds specific to adenosine A2a receptor and uses thereof | ADORA2A, ADORA2B, ADORA3 | RPS6KA5 1436/4885RPS6KA4 2081/4885PIK3CB 2099/4885 |
| US-20020094974-A1 | Compounds specific to adenosine A3 receptor and uses thereof | ADORA3, ADORA2A, ADORA1 | RPS6KA5 2159/4885RPS6KA4 2323/4885PIK3CB 2244/4885 |
| US-20190292189-A1 | LIM KINASE INHIBITORS | LIMK1, LIMK2, LIMA1 | RPS6KA5 946/4885RPS6KA4 748/4885PIK3CB 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.